SIMDAX (Levosimendan) is a calcium sensitizer, it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium, so the demand of Oxygen does not increase, and therefore ischemic attack and mortality are markedly decreased.

Levosimendan exerts its positive (Inotropic effect) by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner.

It also has a (Vasodilatory effect) by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation.

The combined (Inotropic and Vasodilatory actions) result in an increased force of contraction, decreased preload and decreased afterload.

Moreover, by opening also the mitochondrial (ATP)-sensitive potassium channels in cardiomyocytes, the drug exerts a (Cardioprotective effect).

Preparation the solution for infusion:
- SIMDAX is to be diluted prior to admistration as follows: 5 ml SIMDAX are diluted into 250 ml 5% glucose solution in a final concentration of (0.05 mg/ml) levosimendan.

Dosing
- The dose and duration of treatment should be individualised according to the patient’s clinical condition and response.
- Continuous infusion of 0.05 μg/kg/min to 0.2 μg/kg/min (Mostly 0.1 μg/kg/min)

up to 24 hours.
Dosing
- The dose and duration of treatment should be individualised according to the patient’s clinical condition and response.
- Continuous infusion of 0.05 μg/kg/min to 0.2 μg/kg/min (Mostly 0.1 μg/kg/min).
- Infusion up to 24 hours.